RU2711505C9 - Улучшенные экспрессия и процессинг трансгена - Google Patents

Улучшенные экспрессия и процессинг трансгена Download PDF

Info

Publication number
RU2711505C9
RU2711505C9 RU2015127667A RU2015127667A RU2711505C9 RU 2711505 C9 RU2711505 C9 RU 2711505C9 RU 2015127667 A RU2015127667 A RU 2015127667A RU 2015127667 A RU2015127667 A RU 2015127667A RU 2711505 C9 RU2711505 C9 RU 2711505C9
Authority
RU
Russia
Prior art keywords
mar
seq
transgene
cell
expression
Prior art date
Application number
RU2015127667A
Other languages
English (en)
Russian (ru)
Other versions
RU2711505C2 (ru
RU2015127667A (ru
Inventor
ФОРН Валери ЛЯ
Николас МЕРМО
Александр РЕГАМИ
Монтс БЮСЕТА
Дебора ЛЭЙ
Ниам ХАРРАГИ
Кая КОСТИРКО
Пьер-Ален ЖИРО
Давид КАЛАБРЕС
Original Assignee
Селексис С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селексис С.А. filed Critical Селексис С.А.
Publication of RU2015127667A publication Critical patent/RU2015127667A/ru
Publication of RU2711505C2 publication Critical patent/RU2711505C2/ru
Application granted granted Critical
Publication of RU2711505C9 publication Critical patent/RU2711505C9/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2015127667A 2013-02-01 2014-02-01 Улучшенные экспрессия и процессинг трансгена RU2711505C9 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361759802P 2013-02-01 2013-02-01
US61/759,802 2013-02-01
US201361800244P 2013-03-15 2013-03-15
US61/800,244 2013-03-15
US201361806634P 2013-03-29 2013-03-29
US61/806,634 2013-03-29
PCT/IB2014/000100 WO2014118619A2 (en) 2013-02-01 2014-02-01 Enhanced transgene expression and processing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019139048A Division RU2808756C1 (ru) 2013-02-01 2014-02-01 Улучшенные экспрессия и процессинг трансгена

Publications (3)

Publication Number Publication Date
RU2015127667A RU2015127667A (ru) 2017-03-06
RU2711505C2 RU2711505C2 (ru) 2020-01-17
RU2711505C9 true RU2711505C9 (ru) 2020-08-12

Family

ID=50239688

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015127667A RU2711505C9 (ru) 2013-02-01 2014-02-01 Улучшенные экспрессия и процессинг трансгена

Country Status (20)

Country Link
US (1) US11898154B2 (enExample)
EP (2) EP2951309B1 (enExample)
JP (1) JP6563816B2 (enExample)
KR (1) KR102235603B1 (enExample)
CN (2) CN120718957A (enExample)
AU (2) AU2014210856B2 (enExample)
CA (1) CA2898878C (enExample)
DK (2) DK2951309T3 (enExample)
ES (2) ES2717175T3 (enExample)
FI (1) FI3536797T3 (enExample)
HU (2) HUE061494T2 (enExample)
IL (1) IL240198B (enExample)
LT (1) LT2951309T (enExample)
PL (2) PL3536797T3 (enExample)
PT (2) PT3536797T (enExample)
RU (1) RU2711505C9 (enExample)
SG (2) SG11201505487UA (enExample)
SI (1) SI2951309T1 (enExample)
WO (1) WO2014118619A2 (enExample)
ZA (1) ZA201506419B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576265B (zh) * 2014-04-01 2020-08-28 三生国健药业（上海）股份有限公司 一种含mar核心片段的动物细胞表达载体
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
JP6871679B2 (ja) * 2016-03-23 2021-05-12 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
WO2017061354A1 (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
JP2017070224A (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
SG11201805132YA (en) 2015-12-24 2018-07-30 Selexis Sa Improved eukaryotic cells for protein manufacturing and methods of making them
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
EP3219803A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
JP6959942B2 (ja) * 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited タンパク質生成のための脂質代謝のモジュレーション
CN109790539A (zh) * 2016-10-03 2019-05-21 第一三共株式会社 Hspa5基因的启动子
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
KR102523318B1 (ko) 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
WO2018224162A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for characterizing loss of antigen presentation
JP7240749B2 (ja) * 2017-09-29 2023-03-16 ベスファジェン・インコーポレイテッド 心不全の予防または治療のための医薬組成物
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
EP3794128A1 (en) * 2018-05-18 2021-03-24 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
RU2686102C1 (ru) * 2018-08-07 2019-04-24 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
EP3847261A1 (en) * 2018-09-05 2021-07-14 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A method for engineering synthetic cis-regulatory dna
US20210380661A1 (en) * 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
WO2020084528A1 (en) 2018-10-24 2020-04-30 Selexis Sa Expression systems, recombinant cells and uses thereof
US12404527B2 (en) * 2018-12-24 2025-09-02 Selexs S.A. Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
US20220088158A1 (en) 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
EP3946596A4 (en) * 2019-03-27 2022-12-21 Phoenix Tissue Repair, Inc. SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7
CN110006866B (zh) * 2019-04-16 2022-04-22 杭州迈尔德生物科技有限公司 一种阿片类活性物质的通用检测方法及其检测试剂盒
WO2020228721A1 (en) * 2019-05-13 2020-11-19 Lin Mei Chun Method and kit for monitoring cancer
CN114514324A (zh) * 2019-10-10 2022-05-17 加利福尼亚州立大学董事会 稳定哺乳动物细胞的方法
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN110863008B (zh) * 2019-11-22 2020-10-16 昆明学院 Mar序列调控弱启动子构建高效表达载体的方法
AU2020412891A1 (en) 2019-12-24 2022-06-30 Selexis Sa Targeted integration in mammalian sequences enhancing gene expression
BR112022016617A2 (pt) * 2020-02-19 2022-11-22 Wuxi Biologics Ireland Ltd Ácido nucleico, vetor, vetor de transposon, sistema de expressão, ácido nucleico isolado, método para gerar uma célula, célula, método de expressão de uma proteína, proteína, composiçao farmacêutica, sistema de expressão, linhagem celular
CN111500629B (zh) * 2020-04-17 2021-11-19 安徽中盛溯源生物科技有限公司 一种高表达层粘连蛋白-511变体的方法及其应用
EP4149966A4 (en) * 2020-05-14 2024-08-07 Seattle Children's Hospital (DBA Seattle Children's Research Institute) DOUBLE PROMOTOR SYSTEMS
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113881703B (zh) * 2021-10-11 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种提高cho细胞同源重组效率的方法及其相关产品和应用
CN116440269B (zh) * 2022-01-10 2024-02-09 华中农业大学 Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用
CN114958914B (zh) * 2022-06-06 2023-09-26 新乡医学院 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用
CN115896227A (zh) * 2022-12-20 2023-04-04 西北农林科技大学 一种鉴定外源基因整合位点以增强转基因表达的方法
GB202305637D0 (en) 2023-04-17 2023-05-31 Macomics Ltd Transposons, vectors and genetically engineered cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743365A2 (en) * 1995-05-17 1996-11-20 Ajinomoto Co., Inc. Process for efficiently producing transglutaminase through DNA recombination
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2005010046A1 (en) * 2003-06-27 2005-02-03 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
RU2394104C2 (ru) * 2004-05-20 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Аденовирусный/альфа-вирусный гибридный вектор для эффективного введения и экспрессии терапевтических генов в опухолевые клетки
WO2011033375A2 (en) * 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731178A (en) 1990-03-21 1998-03-24 Behringwerke Aktiengesellschaft Attachment-elements for stimulation of eukaryotic expression systems
ATE437233T1 (de) 2001-01-26 2009-08-15 Selexis Sa Matrix-anheftungsregionen und verfahren zu deren verwendung
US20040203158A1 (en) * 2003-01-15 2004-10-14 Hackett Perry B. Transposon-insulator element delivery systems
IN2014DN02484A (enExample) 2003-10-24 2015-05-15 Selexis Sa
WO2007021353A2 (en) * 2005-06-10 2007-02-22 Genentech, Inc. Improving antibody expression using vectors containing insulator elements
CN101855233B (zh) 2007-09-26 2014-05-07 英特瑞克斯顿股份有限公司 合成5’utr、表达载体以及增强转基因表达的方法
US20090247609A1 (en) 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
US20100105140A1 (en) * 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743365A2 (en) * 1995-05-17 1996-11-20 Ajinomoto Co., Inc. Process for efficiently producing transglutaminase through DNA recombination
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2005010046A1 (en) * 2003-06-27 2005-02-03 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
RU2394104C2 (ru) * 2004-05-20 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Аденовирусный/альфа-вирусный гибридный вектор для эффективного введения и экспрессии терапевтических генов в опухолевые клетки
WO2011033375A2 (en) * 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATASCI M. et al. CHO cell lines generated by PiggyBac transposition, BMC PROCEEDINGS, 2011, v. 5, p. P31. *

Also Published As

Publication number Publication date
SG11201505487UA (en) 2015-08-28
CN120718957A (zh) 2025-09-30
IL240198A0 (en) 2015-09-24
JP6563816B2 (ja) 2019-08-21
US11898154B2 (en) 2024-02-13
FI3536797T3 (fi) 2023-03-23
WO2014118619A3 (en) 2014-10-30
RU2711505C2 (ru) 2020-01-17
SI2951309T1 (sl) 2019-04-30
US20150361451A1 (en) 2015-12-17
SG10201803758XA (en) 2018-06-28
PT3536797T (pt) 2023-03-15
PT2951309T (pt) 2019-04-03
CA2898878A1 (en) 2014-08-07
EP3536797B1 (en) 2023-01-04
EP3536797A1 (en) 2019-09-11
ZA201506419B (en) 2017-02-22
PL3536797T3 (pl) 2023-09-11
KR102235603B1 (ko) 2021-04-05
AU2014210856A1 (en) 2015-07-30
ES2717175T3 (es) 2019-06-19
RU2015127667A (ru) 2017-03-06
HK1216323A1 (en) 2016-11-04
IL240198B (en) 2019-10-31
HUE043103T2 (hu) 2019-08-28
ES2940433T3 (es) 2023-05-08
DK2951309T3 (en) 2019-04-23
CA2898878C (en) 2020-04-28
EP2951309B1 (en) 2019-01-30
EP2951309A2 (en) 2015-12-09
KR20150123803A (ko) 2015-11-04
LT2951309T (lt) 2019-03-25
JP2016504922A (ja) 2016-02-18
DK3536797T3 (da) 2023-04-03
DK3536797T5 (da) 2024-09-02
CN105073995A (zh) 2015-11-18
AU2014210856B2 (en) 2019-10-24
WO2014118619A2 (en) 2014-08-07
AU2019250224B2 (en) 2022-05-12
HUE061494T2 (hu) 2023-07-28
PL2951309T3 (pl) 2019-06-28
AU2019250224A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
AU2019250224B2 (en) Enhanced transgene expression and processing
AU2020274339B2 (en) Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
AU2022201296B2 (en) Genetically modified cells, tissues, and organs for treating disease
AU2022200903B2 (en) Engineered Cascade components and Cascade complexes
KR102784788B1 (ko) 오리지아스로부터의 트랜스포사제를 이용한 핵산 작제물의 진핵세포로의 통합
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
KR102799185B1 (ko) 아마이엘로이스로부터의 트랜스포사제를 이용한 핵산 작제물의 진핵세포 게놈으로의 전위
KR20120099376A (ko) 강화된 전이 유전자 발현과 공정 방법 및 그 산물
KR20200126997A (ko) 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법
KR101476010B1 (ko) 고생산성 세포의 수립을 위한 발현 벡터 및 고생산성 세포
KR20220157944A (ko) 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
TW201207103A (en) DNA element having the activity of enhancing foreign gene expression
CN109790539A (zh) Hspa5基因的启动子
RU2814721C2 (ru) Транспозиция конструкций нуклеиновой кислоты в эукариотические геномы с транспозазой из amyelois
RU2817770C2 (ru) Интеграция конструкций нуклеиновой кислоты в эукариотические клетки с транспозазой из oryzias
RU2829170C1 (ru) Адресное встраивание в последовательности млекопитающих, усиливающее экспрессию генов
RU2827658C2 (ru) Сконструированные компоненты cascade и комплексы cascade
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade

Legal Events

Date Code Title Description
TH4A Reissue of patent specification